Both infliximab and adalimumab are safe and effective in achieving remission in patients with severe mucocutaneous Behçet syndrome, with adalimumab demonstrating a quicker response time; both drugs ...

Behçet's disease (BD) is a multisystem inflammatory disorder currently classified as a vasculitis. Its etiopathogenesis is unclear, but environmental, genetic and autoimmune factors have been ...

Behcet's syndrome (BS) is a rare disorder of unknown etiology. Also known as Adamantiades-Behcet's syndrome, it is a multisystem complication of the inflammatory system. It is a combination of ...

Please provide your email address to receive an email when new articles are posted on . Week-22 remission rates were 81% among patients using infliximab and 56% in those on cyclophosphamide. Mild to ...

PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

Please provide your email address to receive an email when new articles are posted on . Adalimumab plus corticosteroids significantly outperformed cyclosporine plus corticosteroids to delay Behçet’s ...

PRINCETON, N.J., Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

Behçet's syndrome is a form of autoimmune vasculitis marked by widespread and sometimes life-threatening cardiovascular complications, as well as skin, nervous system, and gastrointestinal lesions.

Soligenix Inc.’s phase IIa study of SGX-945 (dusquetide) for treating oral ulcers in those with Behçet's disease showed biological efficacy in the proof-of-concept study. The positive results ...

Dr. Javier A. Suarez (Neurology): A 32-year-old man was admitted to this hospital after 2 weeks of confusion and headache and 2 days of fever. The patient had been in his usual state of health until 1 ...